Aug 29, 2006 · The mammalian target of rapamycin (mTOR) is a protein that is intricately involved in signaling pathways controlling cell growth. Rapamycin is a natural product that binds and …

May 1, 2013 · In mTOR, the ∼ 100-residue FRB domain is thought to occur between the FAT domain and the catalytic domain, and the region amino terminal to the FAT domain is required …

Rapamycin is an immunosuppressive drug that binds simultaneously to the 12-kDa FK506- and rapamycin-binding protein (FKBP12, or FKBP) and the FKBP-rapamycin binding domain …

Here we present the 3.2 Å crystal structure of a ~1500 amino acid mTOR-mLST8 complex containing the FAT, FRB, kinase and FATC domains, as well as the structures of this complex …

The mammalian target of rapamycin (mTOR), [5] also referred to as the mechanistic target of rapamycin, and sometimes called FK506-binding protein 12-rapamycin-associated protein 1 …

Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and …

Aug 6, 2007 · Here, we report the solution structures of complexes formed between the FKBP12-rapamycin binding (FRB) domain of mTOR and phosphatidic acid, an important cellular …

Dec 1, 2014 · mTOR contains a canonical two-lobe kinase domain (KD) spanning about 550 C-terminal residues, with three characteristic insertions: FATC (∼30 residues), LBE (∼40 …

Aug 3, 2020 · We selected FRB (human mammalian target of rapamycin (mTOR) residues 2021–2113) with a T2098L mutation, which makes it otherwise unstable unless bound to …

Jun 29, 2017 · We also present crystal structures of RAPTOR-TOS motif complexes that define the determinants of TOS recognition, of an mTOR FKBP12-rapamycin-binding (FRB) domain …